Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

Pfizer Inc has acquired exclusive rights to commercialise an obesity therapy in China, strengthening its push into the ...

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Sciwind said the agreement marks “an important first step to advance Pfizer's global strategy in the metabolic field in China ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes. ・The company plans to launch more than 20 trials in 2026, ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings. Read more on PFE & JNJ stocks here.

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its ...

Pfizer's dividend yield is a lofty 6.2%. That's well above the 1.1% yield offered by the S&P 500 index and the 1.7% yield of the average pharmaceutical stock. And the company recently provided ...

Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 - ...